Utheim, Mari Nythun
Isaakidis, Petros
Van den Bergh, Rafael
Géraud, Bantas Bata Ghislain
Mabvouna, Rodrigue Biguioh
Omsland, Tone Kristin
Heen, Espen
Dahl, Cecilie
Article History
Received: 23 June 2022
Accepted: 9 February 2023
First Online: 27 March 2023
Declarations
:
: The study was approved by the Norwegian Centre for Research Data (NSD), Oslo, Norway, the Comité Scientifique Chargé de la Validation des Protocoles d’Etudes et des Résultats (ref n° _15_/UB/FACSS/CSCVPER/18) in Bangui, CAR and the MSF Ethics Review Board, Geneva, Switzerland. Given the vulnerability of participants, confidentiality was given high priority. The patient flow was arranged for study participation and HIV testing to be inconspicuous. All staff involved in the study had confidentiality agreements. No incentive was given for participation. All health services were provided free of charge regardless of participation. Participants were informed about this before consenting or refusing to participate. Consent was documented in a consent form that was read out to each participant. Participant data on paper was kept locked in a secure cabinet, and data were entered and stored in a secure platform for sensitive data (Tjenester for Sensitive Data (TSD), University of Oslo).
: Not applicable.
: None of the authors have competing interests.